Business
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting
WARREN, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to
About this update from Aquestive Therapeutics, Inc.
[{"type":"text","content":"WARREN, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, will present three abstracts recapping positive data from its completed pharmacokinetic studies of AQST-109 (epinephrine sublingual film) at the American College of Allergy Asthma and Immunology (ACAAI) Annual Scientific Meeting, which will be held from November 10-14, in Louisville, Kentucky. “Not only are we excited to share the positive results from our two completed AQST-109 pharmacokinetic studies, but we are also honored to have results selected for presentation as a Distinguished Industry Oral Abstract, with the opportunity to highlight the formulation and dosage from the podium,” said Ken Truitt, M.D., Aquestive’s Chief Medical Officer. “We look forward to connecting with leaders in the allergy community and providing insight on how our research has the potential to provide an important advance in the treatment of acute allergic reactions.” Poster Details: Abstract Title: Pharmacokinetics Study of Epinephrine Sublingual Film: Results from The Formulation and Dosage Selection Presentation ID: D001Session: Distinguished Industry Oral Abstracts- Session BPodium Presentation Time: Saturday, November 12, 4:53 - 5:03 PM ETLocation: Room M104-M107Presenting Author: Dr. John Oppenheimer, MD (UMDNJ Rutgers University School of Medicine) Abstract Title: Minimal Impact of Food, Drink, Or Temperature on The Pharmacokinetics of a Sublingual Film Using a Novel Prodrug of Epinephrine (DESF)Presentation ID: ID: P022Category: Adverse Drug Reactions, Insect Reactions, AnaphylaxisPresentation Time: Sunday, November 13, 12:35 PM ETLocation: Exhibit Hall (Upper Concourse), Monitor 9Presenting Author: Holly Ponichtera, PhD (Aquestive Therapeutics) Abstract Title: Results of a Repeat Dose Study on The Pharmacokinetics of a Sublingual Film using a Novel Prodrug of Epinephrine (DESF)Presentation ID: ID: P021Category: Adverse Drug Reactions, Insect Reactions, AnaphylaxisPresentation Time: Sunday, November 13, 12:20 PM ETLocation: Exhibit Hall (Upper Concourse), Monitor 9Presenting Author: Holly Ponichtera, PhD (Aquestive Therapeutics) About AnaphylaxisAnaphylaxis is a serious systemic hypersensitivity reaction with rapid o...